eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
5/2022
vol. 39
 
Share:
Share:
more
 
 
abstract:
Original paper

Factors affecting the choice of budesonide in the therapy of croup, asthma and chronic obstructive pulmonary disease

Magdalena Olszanecka-Glinianowicz
1
,
Jerzy Chudek
2
,
Anna Urcus
3
,
Agnieszka Almgren-Rachtan
4

1.
Health Promotion and Obesity Management Unit, Department of Pathophysiology, Medical Faculty in Katowice, Medical University of Silesia, Katowice, Poland
2.
Department of Internal Medicine and Oncological Chemotherapy, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland
3.
Adamed Pharma, Poland
4.
Pharmacovigilance Department, Europharma, Katowice, Poland
Adv Dermatol Allergol 2022; XXXIX (5): 893-901
Online publish date: 2022/11/09
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Budesonide is one of inhaled corticosteroids with an established position in the therapy of croup, bronchial asthma and chronic obstructive pulmonary disease (COPD).

Aim
To assess factors affecting the choice of budesonide in the therapy of croup, asthma and COPD by specialists and general practitioners in daily clinical practice.

Material and methods
This multicentre, open-label, post-marketing survey was performed nation-wide with the participation of 1113 doctors and 100,980 patients treated with budesonide. The study questionnaire included questions about factors affecting the choice of budesonide and assessing the prescription pattern of the drug.

Results
The doctors frequently declared use of budesonide in monotherapy in patients with croup, and in polytherapy in asthma and COPD (with salmeterol or formoterol and with formoterol, respectively). The most important factors affecting the choice of budesonide, as declared by doctors, were safety, efficacy, good personal experience with the use of this medication and recommendations of scientific associations. Budesonide in monotherapy was prescribed in 63.7%, 49.7%, and only 13.5% of patients with croup, asthma and COPD, respectively. The most important factors which determined the choice of this drug were safety (from 78.7% to 91.0%), efficacy (from 78.9% to 90.5%) and good personal experience of doctors (from 65.6% to 84.5%).

Conclusions
Budesonide is still frequently chosen in the treatment of croup, asthma and COPD by Polish specialists and general practitioners because of its efficacy, safety and considerable experience in the application. Acquired clinical experience of physicians prevails over the issued recommendations of scientific societies regarding the use of budesonide in daily clinical practice.

keywords:

croup, asthma, chronic obstructive pulmonary disease, budesonide, therapeutic preferences, efficacy, safety

Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.